Combinations of PARPi with other drugs are now being intensively investigated to prevent the development of resistance to PARPi and to extend their use beyond BRCA1/2-deficient tumors including HCC [47–49]. This evidence concerns the gene BRCA1 and hepatocellular carcinoma.